Fundraise
Donate
Home/Research/AS Natural History Study Celebrates 20 Years!

AS Natural History Study Celebrates 20 Years!

For two decades, the Angelman Syndrome Natural History Study has been building data that drives discovery.

Thanks to the dedication of clinicians, researchers, coordinator, individuals with Angelman syndrome, and their families, the AS Natural History Study has become a beacon of progress.

ASF and FAST are proud to celebrate this milestone with the Natural History Study team and the community that made it happen.

Read the full celebrations in the January 2026 AS Natural History News

If you are interested in participating in the AS Natural History, check out the study details on Clinicaltrials.gov

Related News

  • Research

Beyond UBE3A: New Conversations About Genotype, Variants, and Future Treatments

At INSYNC-AS 2026, researchers came together to examine how genes beyond UBE3A and differences within UBE3A itself may shape Angelman syndrome and future therapeutic development. Why can Angelman syndrome (AS)

  • Industry, Research

Foundation for Angelman Syndrome Therapeutics Announces Agreement with Apertura Gene Therapy for Access to Blood-Brain Barrier-Crossing Capsid

Read the press release

  • Research

Nobel Laureate Frances Arnold Brings Directed Evolution to Angelman Syndrome Research

Nobel laureate Dr. Frances Arnold receives FAST funding to engineer new molecular tools for durable RNA-targeted therapies, bringing world-class expertise to Angelman syndrome research.
  • Research

FAST at ASGCT 2026

FAST leadership takes the stage at ASGCT's Annual Meeting, driving key conversations on gene therapy, clinical collaboration, and patient advocacy shaping Angelman syndrome research.
  • Research

Non-viral delivery gene editing takes an important step forward for Angelman syndrome

A FAST-funded study unveils STEP-RNP, a non-viral gene editing platform showing improved motor, cognitive function in AS mice—an early but promising step toward treating Angelman syndrome.
  • Research

FAST LATAM Brings Families and Research Together in Mexico City

The second FAST LATAM Conference in Mexico City drew 267 in-person and nearly 496 virtual attendees, uniting families across the region around research updates and shared hope.
View More News

What are you looking for?

Find information on Angelman syndrome, research, clinical trials, resources, and ways to get involved.